Literature DB >> 34413938

Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists May Provide a Superior Treatment for Pain and Migraine.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2021        PMID: 34413938      PMCID: PMC8365616          DOI: 10.1021/acsmedchemlett.1c00333

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  4 in total

Review 1.  Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015-2019).

Authors:  Huifen Chen; Jack A Terrett
Journal:  Expert Opin Ther Pat       Date:  2020-08-25       Impact factor: 6.674

Review 2.  The TRPA1 Channel in the Cardiovascular System: Promising Features and Challenges.

Authors:  Zhen Wang; Di Ye; Jing Ye; Menglong Wang; Jianfang Liu; Huimin Jiang; Yao Xu; Jishou Zhang; Jiangbin Chen; Jun Wan
Journal:  Front Pharmacol       Date:  2019-10-18       Impact factor: 5.810

Review 3.  TRPA1 as a therapeutic target for nociceptive pain.

Authors:  Daniel Souza Monteiro de Araujo; Romina Nassini; Pierangelo Geppetti; Francesco De Logu
Journal:  Expert Opin Ther Targets       Date:  2020-09-11       Impact factor: 6.902

4.  TRPA1: An asthma target with a zing.

Authors:  Sven-Eric Jordt
Journal:  J Exp Med       Date:  2021-04-05       Impact factor: 14.307

  4 in total
  1 in total

1.  Inhibition of Nociception in a Preclinical Episodic Migraine Model by Dietary Supplementation of Grape Seed Extract Involves Activation of Endocannabinoid Receptors.

Authors:  Sara E Woodman; Sophia R Antonopoulos; Paul L Durham
Journal:  Front Pain Res (Lausanne)       Date:  2022-01-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.